Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Spinal Muscular Atrophy Market studies Research Report
Report Description
Spinal muscular atrophy (SMA) is a hereditary au...
This results in motor neurons to lose control over voluntary
muscle movement. SMA is a leading fatal genetic disease
among...
Type 2 SMA is a moderate form affecting children aged
between six months and eighteen months. Type 3 and 4 are
less severe...
disease to extend range of motion and improve muscle
flexibility. Spinal muscular atrophy drugs pipeline is dry;
however, ...
Inquiry for Check discount @
http://www.mrrse.com/checkdiscount/1417 

Olesoxime (TRO19622) has completed its phase2/3 tri...
MRRSE stands for Market Research Reports Search Engine,
the largest online catalog of latest market research reports
based...
Corporate Office
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-730-0559
Email: sales@m...
Upcoming SlideShare
Loading in …5
×

Spinal muscular atrophy market studies research report

194 views

Published on

MRRSE has announced the addition of the “Spinal Muscular Atrophy Market - Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023” report to their offering.

Published in: Healthcare
  • Be the first to comment

Spinal muscular atrophy market studies research report

  1. 1. Spinal Muscular Atrophy Market studies Research Report Report Description Spinal muscular atrophy (SMA) is a hereditary autosomal recessive disease affecting areas of the nervous system that control voluntary muscle movement. Mutation in survival motor neuron (SMN) gene causes deficiency of SMN protein.
  2. 2. This results in motor neurons to lose control over voluntary muscle movement. SMA is a leading fatal genetic disease among infants; where one infant in 6,000 births is estimated to suffer from SMA. Furthermore, over 10 million people in the U.S. are carriers of SMA gene. Based on the age of onset and symptoms, spinal muscular atrophy has been classified in four main types: type 1, type 2, type 3, and type 4, and thus the respective markets. Each of these types has a characteristic disease progression and defined mortality rate. Type 1 SMA is the most severe form, and affects infants aged between zero and six months. Approximately 65% of these cases are of type 1 SMA, wherein infants usually do not survive for more than 2 years.
  3. 3. Type 2 SMA is a moderate form affecting children aged between six months and eighteen months. Type 3 and 4 are less severe and usually have a normal lifespan. Spinal muscular atrophy is diagnosed by identifying mutation in survival of motor neuron (SMN) gene. Other diagnostic tests include muscle biopsy, electromyogram (EMG), and nerve conduction velocity. Request For Sample Copy Of Report @ https://goo.gl/YUZZjp Currently, no cure exists for spinal muscular atrophy, and the treatment is targeted towards symptoms management. Physiotherapy is strongly recommended in early stages of the
  4. 4. disease to extend range of motion and improve muscle flexibility. Spinal muscular atrophy drugs pipeline is dry; however, it has three drugs in phase 1, three in phase 2, and one in phase 3 clinical trials. ISIS-SMNRx, an antisense therapy candidate by Isis Pharmaceuticals, is currently under phase 3 studies for treatment of type 1 and 2 SMA. If approved, ISIS-SMNRx would be the only drug available of the treatment of spinal muscular atrophy, creating lucrative opportunity for Isis Pharmaceuticals and Biogen Idec. Phase 3 study is expected to complete in June 2017. The drug is projected to record sales of USD 468.2 million in the U.S. by 2023.
  5. 5. Inquiry for Check discount @ http://www.mrrse.com/checkdiscount/1417 Olesoxime (TRO19622) has completed its phase2/3 trials, and has shown promising results, with potential to effectively treat type 2 and type 3 SMA. Other potential candidates include Olesoxime (TRO19622), LMI070, RO6885247, CK- 2127107, scAAV9.CB.SMN and RG3039. Key players with potential therapeutics in clinical trial phase include AveXis, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Isis Pharmaceuticals, Inc. About MRRSE
  6. 6. MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies. Contact US:
  7. 7. Corporate Office State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Tel: +1-518-730-0559 Email: sales@mrrse.com

×